Skip to NavigationSkip to content

News

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin disease...
The collaborative efforts of Domainex and Auspherix have made new progress in the development of a solution to the growing threat of antibiotic...
Recent Phase 3 data for Sanofi and Regeneron's Dupixent in uncontrolled asthma was positive, boasting superior data to competitors, but did not...
Novartis has unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the...
23andMe made two announcements on the same day that point towards the future of its business: it revealed it had raised $250 million in financing and...
The Fluad flu vaccine, produced by Seqirus, was approved by the MHRA for use beginning in 2018 and further data has been released to back up this...
Johnson and Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C...
Shortly after the news that Teva had finally sealed the deal on a new CEO, it also announced that it had managed to sell its contraceptive brand...
Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a proposed...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches